Neuroprotective Effects of AMP-Activated Protein Kinase on Scopolamine Induced Memory Impairment

Soo-Jeong Kim1,*; Jun-Ho Lee1,*; Hwan-Suck Chung1; Joo-Hyun Song1; Joohun Ha2; and Hyunsu Bae1,3

1College of Korean Medicine, 2School of Medicine, 3Institute of Oriental Medicine, Kyung Hee University, Seoul 130-701, Korea

AMP-activated protein kinase (AMPK), an important regulator of energy metabolism, is activated in response to cellular stress when intracellular levels of AMP increase. We investigated the neuroprotective effects of AMPK against scopolamine-induced memory impairment in vivo and glutamate-induced cytotoxicity in vitro. An adenovirus expressing AMPK wild type alpha subunit (WT) or a dominant negative form (DN) was injected into the hippocampus of rats using a stereotaxic apparatus. The AMPK WT-injected rats showed significant reversal of the scopolamine induced cognitive deficit as evaluated by escape latency in the Morris water maze. In addition, they showed enhanced acetylcholinesterase (AChE)-reactive neurons in the hippocampus, implying increased cholinergic activity in response to AMPK. We also studied the cellular mechanism by which AMPK protects against glutamate-induced cell death in primary cultured rat hippocampal neurons. We further demonstrated that AMPK WT-infected cells increased cell viability and reduced Annexin V positive hippocampal neurons. Western blot analysis indicated that AMPK WT-infected cells reduced the expression of Bax and had no effects on Bcl-2, which resulted in a decreased Bax/Bcl-2 ratio. These data suggest that AMPK is a useful cognitive impairment treatment target, and that its beneficial effects are mediated via the protective capacity of hippocampal neurons.

Key Words: Adenovirus, AMPK, Apoptosis, Learning and memory, Scopolamine

INTRODUCTION

Energy homeostasis is essential for the survival of any organism. Many reports have shown that the mechanisms of energy metabolism may play an important role in mediation of aspects of higher order cognitive function [1]. Cellular energy status is monitored and controlled by the adenosine monophosphate-activated protein kinase (AMPK) system. AMPK functions as an energy metabolic sensor when cells are subjected to energy-depleting stresses. Elevations in intracellular AMP concentration and corresponding decreases in ATP levels serve as critical factors in the stimulation of AMPK activity [2]. AMPK is allosterically activated by AMP, which accumulates following ATP hydrolysis. AMPK is a heterotrimeric complex consisting of a catalytic alpha subunit and regulatory beta and gamma subunits, each of which is encoded by two or three distinct genes (alpha 1, 2, beta 1, 2 and gamma 1, 2, 3) [3,4]. All combinations of isoforms appear to be able to form complexes, which when combined with splice variants and the use of alternative promoters leads to a diverse array of different AMPK complexes [4]. Aspartate 157 within the alpha subunit lies in the conserved DFG motif, which has been shown to be essential for MgATP binding in all protein kinases [5,6]. Mutation of this residue to alanine in either alpha1 or 2 yields an inactive kinase, but has no effect on binding of the beta and gamma subunits within the complex [5,7]. Since formation of the heterotrimeric complex is essential for AMPK activity, we reasoned that over-expression of the inactive alpha1 subunit would act as a dominant negative inhibitor by competing with the native alpha subunit for binding with beta and gamma [5].

AMPK was recently reported to be regulated by a calcium signal and to protect neuronal cells from glucose deprivation and exposure to glutamate [8,9]. Zhao et al. showed that AMPK acts as a molecular target for the treatment of neurodegenerative disorders including glutamate-induced epileptic seizure and ischemic injury, particularly through regulation of BDNF expression [10]. AMPK has also been shown to play a protective role in cerebral metabolic stress [11]. Through appropriate modulation of gene transcription, AMPK enhances the capacity of the cell to gen-
erate ATP [12,13]. Accordingly, the regulation of metabolism by AMPK ensures cell survival during energy depletion [4,13]. Moreover, AMPK inhibits cell growth and protects against suicidal cell death or apoptosis [4,12].

In the present study, intraperitoneal (i.p.) administration of scopolamine, a muscarinic cholinergic receptor antagonist, was exploited as a pharmacological model for AD in rats. Scopolamine interferes with central cholinergic functions and memory circuits, leading to decreased Ach release and subsequent memory, attention, and executive function-related deficits that are seen in aging and dementia [4,12]. Due to this, scopolamine-induced cognitive dysfunction is extensively used to probe potential therapeutic agents attenuating cognitive deficits [15]. In the Morris water maze, systemic administration of scopolamine has been reported to be more effective in disrupting learning and acquisition, and short-term retention of spatial memory [16]. Besides, scopolamine-induced amnesia is relevant to decreased glucose oxidation, increase in brain oxidative [17,18] and decrease of ATP levels in the brain [19,20].

Neurotoxicity in the mammalian CNS has been relevant to glutamate. Glutamate-induced excitotoxicity has been linked to neuronal cell death, including periods of acute neuronal injury as anoxia and reperfusion that may account for the neuronal injury in neurodegenerative diseases such as AD [21-23]. Glutamate-induced neuronal damage is initiated by elevation of the intracellular cation level followed by activation of catabolic enzymes such as proteases, phospholipases and many kinases, as well as the formation of radical oxygen species, which induces cell death via a process known as necrosis or apoptosis [24,25]. Necrosis is characterized by cell swelling, organelle damage, depletion of ATP, loss of ion balance, membrane disorder, nuclear lysis, cessation of protein synthesis, and promotion of the death of adjacent cells, whereas apoptosis is characterized by cell loss, maintenance of the ATP level and ion balance, DNA fragmentation, and a lack of adverse effects on adjacent cells [24,26].

In this study, we investigated the effects of AMPK on scopolamine-induced memory deficit in rats and the protective effect of AMPK on glutamatergic excitatory neurotoxicity in primary cultured hippocampal neurons. To accomplish this, we used the two active and inactive AMPK subunits, c-myc-tagged AMPK wild type alpha subunit (Ad-AMPK-WT) and a dominant negative form (Ad-AMPK-DN), in which Asp157 was replaced with alanine [5]. The results suggest that AMPK plays important roles leading to the cognitive improvement of scopolamine-induced amnesia and that it reduces glutamate-induced cell death. These behavioral and neurochemical results indicate that AMPK has potent cognitive enhancing effects and neuroprotective activities against scopolamine-induced memory impairment. Based on the observations presented herein, we propose that AMPK is a crucial factor involved in cognition function and neuroprotection.

METHODS

Animals

Male Sprague-Dawley rats (250 ~ 280 g) purchased from Orient Animal Corp. (Korea) were housed in groups of four in a controlled environment (12 : 12-hour light : dark cycle, temperature 23±2°C, humidity 50±10%) with water and food available ad libitum for seven days before starting the experiments. All experiments in this study were approved by the Institutional Animal Care and Use Committee of Kyung Hee University. The rats were randomly assigned to three groups (21 rats in each group): group 1: AMPK dominant negative form + saline; group 2: AMPK dominant negative form + scopolamine 2 mg/kg, group 3: AMPK wild type α subunit + scopolamine 2 mg/kg.

Adenovirus-mediated gene transfer

c-myc-tagged AMPK wild type α subunit (Ad-AMPK-WT) and a dominant negative form (Ad-AMPK-DN), in which Asp157 was replaced with alanine, were kindly provided by Prof. Ha, Kyunghee University, Seoul, Korea. Small-volume aliquots were kept in liquid nitrogen, and fresh aliquots were used for each experiment. AMPK was infected with recombinant adenovirus at concentrations of 109~1010 pfu/ml.

Microinjection of adenovirus into the hippocampal CA3

Rats were positioned in a stereotactic instrument (Stoelting, USA) under isoflurane anesthesia. After making a longitudinal incision of the scalp and cleaning the exposed dorsal cranium, a hole was drilled in the skull over the hippocampal CA3 [−5.3 mm anterior-posterior, −5.0 mm mediolateral, −6.0 mm dorsoventral, according to the rat brain atlas]. Next, a 10 μl Hamilton syringe (30 gauge beveled needle) attached to a stepper motorized nano-injector (Stoelting) was filled with 3 μl of viral suspension, which was injected unilaterally into the hippocampus at a rate of 0.2 μl/min using a microinjection pump (Reno, NV, USA). After injection, the syringe was left in place for 10 min, and then withdrawn very slowly over 10 min. The skin was subsequently sutured with silk, and the rats were then allowed to recover from surgery. At seven days after surgery, the scopolamine (2 mg/kg, ip) or saline was administered 30 min before the rats were subjected to the water maze task. The correct injection of adenovirus was verified by Cresyl violet staining of the hippocampus CA3 and subsequent microscopic analysis (Zeiss, Germany) at the end of the study (Fig. 1).

Primary hippocampal neuron culture and treatment

Pregnant Sprague-Dawley rats were purchased from Oriental bio Laboratory animal center. Rat hippocampal neuron cultures were prepared according to Lee et al. [27], with modifications. Briefly, rat brains were dissected from 17- to 18-day-old rat embryos, miniced in L-15 medium, and incubated at 37°C for 15 min with 0.125% trypsin. Dulbecco's modified Eagle’s medium containing 10% fetal calf serum, 10% heat-inactivated horse serum, penicillin (100 U/ml) and streptomycin (100 μg/ml) was then added, after which the cells were centrifuged at 600 g for 1 min, resuspended in the above medium, triturated with the aid of a fire-polished Pasteur pipette, and plated onto poly(l-lysine)-coated (10 μg/ml) 35-mm culture dishes (1.5×10⁶ cells/dish). After 1 day, the medium was replaced with fresh F-12 medium supplemented with 5 μg/ml insulin, 1 μg/ml transferrin, 20 nM hydrocortisone, 30 nM triiodothyronine, 2 μg/ml carnitine, and 15 nM selenium oxide (Medium A). The cells were maintained in Dulbecco's modified Eagle's medium for seven days before use. After seven days of culture in vitro, hippocampal neurons were transfected with...
Ad-AMPK-WT and Ad-AMPK-DN in each group, followed by exposure to 100 μM glutamate with 10 μM of glycine in supplemented neuronal culture medium for 15 min at 37°C in a humidified incubator with an atmosphere composed of 5% CO₂/95% air. After excitotoxicity was induced, the cells were further incubated with the neuronal culture medium at 37°C.

Morris water maze test

A modified version of the procedure described by Morris was used [28]. The water maze was a circular pool (2.0 m in diameter and 0.35 m in height) constructed of fiberglass. The pool contained water maintained at a temperature of 22±2°C and 1 kg of powdered skim milk to make the water opaque. During testing in the water maze, a platform (15 cm in diameter) was fixed at 1.5 cm below the surface of the water in one of four locations, approximately 50 cm from the side walls. The pool was surrounded by different extra-maze cues. Each trial was initiated at one of four different starting positions and the out of the pool and swimming path of each rat was recorded by a video camera connected to a video recorder and a tracking device (S-MART, Pan-Lab, Spain). All rats were subjected to four trials per day with an interval of 15 min for four consecutive days, followed by one day of probe trials on the fifth day. The trials were completed when the rat found the hidden platform or the escape latency reached 180 s. For the probe trial, the platform was removed from the pool and the rat was allowed to swim freely for 60 s to search for the previous location of the platform. The proportion of time spent searching for the platform in the training quadrant, i.e. the previous location of the platform, was used as a measure of memory retention.

Western blot analysis

For phosphor-AMPK (p-AMPK), AMPK, and c-Myc protein analysis, hippocampal lysates (50 μg per lane) were separated by 10% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) followed by electrophoretic transfer onto a nitrocellulose membrane (Millipore, MA, USA). The membranes were then probed with antibodies to AMPK α-Thr172 (2531, Cell Signaling Technology, MA, USA), AMPK α (07181, Upstate Biotechnology, Lake Placid, NY), c-Myc (sc764, Santa Cruz Biotechnology, CA) and α-actin (sc17829, Santa Cruz Biotechnology, CA). To assess cell apoptosis, 5~10 μg of cell extracts were analyzed by SDS-PAGE using the antibodies listed below. Antibodies for Bcl-2 (2876) and Bax (2772) were purchased from Cell Signaling Technology. The antibody-specific proteins were visualized using the enhanced chemiluminescence detection system according to the recommended procedure (Amersham Corp., Newark, NJ).

Flow cytometric analysis

Hippocampal neurons were incubated with FITC Annexin V in buffer and then analyzed by flow cytometry. Briefly, hippocampal neurons were washed twice with cold PBS and then resuspended in buffer (0.1 M Hepes/NaOH (pH 7.4), 1.4 M NaCl, 25 mM CaCl₂) at a concentration of 1×10⁶ cells/ml. Next, 100 μl of the solution were transferred to a 5 ml culture tube. FITC Annexin V was added (5 μl) to the culture tube and incubated for 15 min at RT (25°C) in the dark. After incubation, cells were resuspended in 400 μl of buffer and Annexin V positive cells were detected by flow cytometry (FACS Caliber, BD, San Diego, CA, USA) and then analyzed using the CellQuest software.

AChE histochemistry

For neurobiological analysis (n=20 per group), rats were perfused transcardially via the ascending aorta with normal saline (0.9%), followed by 4% paraformaldehyde in 0.1 M phosphate-buffered saline (PBS). The brains were then removed, post-fixed overnight and immersed sequentially in 0.1 M PBS containing 20% sucrose at 4°C until they sank. The brains were then cut into 40 μm coronal sections using a cryostat, after which the sections were washed in PBS and then incubated in a solution containing 25 mg acetylcholine iodine for 1 h. The solution was composed of 32.5 ml of 0.1 M sodium hydrogen phosphate buffer (NaH₂PO₄·H₂O, pH 6.0), 2.5 ml of 0.1 M sodium citrate, 5 ml of 30 mM copper sulfate, 5 ml of 5 mM potassium ferricyanide and 5 ml of distilled water. The color of the mixing solution was green. The density of the stained nuclei of the hippocampal cells from the hippocampal CA1 and CA3 areas were measured using the Scion image program (Scion Corp., MD, USA).

Statistical analysis

The data were expressed as the means±SEM. Differences
between groups were analyzed by repeated measures analysis of variance (ANOVA) using SPSS (Version 10.0; SPSS Inc., Chicago, USA). ANOVA followed by Tukey’s post hoc test for multiple group comparison was used to analyze differences in data collected on successive training days, during the probe trials, and during the neurobiological analysis. Differences among groups were considered statistically significant if the associated probability (p-value) was < 0.05.

RESULTS

AMPK reverses spatial learning deficits induced by scopolamine

To determine if adenoviral gene transfer of Ad-AMPK-DN and -WT into the hippocampus affects special memory tasks, we evaluated the effect of AMPK on scopolamine-induced impairment of memory by the Morris water maze test. In this study, scopolamine treatment had a significant effect on escape latency (the swimming time required to find a hidden platform in the acquisition test) and total swimming distance (the swim path length taken to find the hidden platform in the acquisition test) among Ad-AMPK-DN injected rats. Conversely, scopolamine-induced memory deficiency was significantly alleviated in Ad-AMPK-WT injected rats when compared with Ad-AMPK-DN injected rats. As shown in Fig. 2A, the results of the escape latency revealed a significant difference between groups \( [F(2, 60)=78.98, p<0.001] \) and time of day \( [F(3, 180)=56.32, p<0.001] \). On days 1 ∼ 4, the AMPK-WT + scopolamine group showed significantly reduced escape latency when compared with the AMPK-DN + scopolamine group (\( p<0.05 \) on day 1 and \( p<0.001 \) on days 2 ∼ 4).

As shown in Fig. 2B, the total swimming distance differed significantly among groups \( [F(2, 60)=51.22, p<0.001] \) and time of day \( [F(3, 180)=8.24, p<0.001] \). Post hoc analysis revealed that the AMPK-DN + scopolamine group had significantly increased swimming distance when compared with the AMPK-DN + saline group during all of the training days (\( p<0.001 \)). On days 2 ∼ 4, the AMPK-WT + scopolamine group showed a significantly decreased swimming distances when compared with the AMPK-DN + scopolamine group (\( p<0.05 \) on days 2 ∼ 4). Conversely, there was no significant difference in the average swimming speed among groups on all training days (data not shown).

The performance on the probe trial for comparing the percentage of time spent swimming around the platform on day 5 is illustrated in Fig. 2C. Post hoc analysis of learning and memory retention performance revealed that the AMPK-DN + saline group and the AMPK-WT + scopolamine group spent a longer time around the platform than the AMPK-DN + scopolamine group (\( p<0.05 \) and \( p<0.05 \)). Moreover, analysis of the performance during the probe trial for comparing the swimming distance around the platform is illustrated in Fig. 2D. Post hoc analysis of learning and memory retention performance also revealed that the AMPK-DN + saline group and the AMPK-WT + scopolamine group had a significantly longer swim distance around the platform than the AMPK-DN + scopolamine group (\( p<0.05 \) and \( p<0.05 \)). These findings indicate that scopolamine severely impaired the spatial memory properties in the water maze test, but that adenoviral gene transfer of Ad-AMPK-WT ameliorated the scopolamine induced cognitive deficit.

AMPK causes an increase in the AChE-reactive neurons in the hippocampus

We measured the levels of AChE-reactive neurons at the hippocampal CA1 and CA3 using AChE histochemistry.
AMPK Protects from Cognitive Defects

Fig. 3. Density of the AchE-reactive neurons in hippocampal CA1 and CA3 of the experimental groups. AchE positive nerve fibers in the hippocampal CA1 (A) and CA3 (B) molecular layer of experimental rats in AMPK-DN+ saline group (a, d), AMPK-DN+ scopolamine group (b, e), and AMPK-WT+ scopolamine group (c, f). The brains were cut into 40 μm coronal sections and the scale bar represents 50 μm (100× magnification). The percentage of AMPK-DN+ saline values of the density of acetylcholinesterase (AChE) stained nuclei in the hippocampal CA1 (C) and CA3 (D) areas after the water maze test. Data were analyzed using one-way ANOVA followed by the Tukey’s test. Each value represents the mean±SEM. *p<0.05 compared to AMPK-DN+ scopolamine.

Fig. 3A shows the distribution of AChE-reactive neurons in the hippocampus of the AMPK-DN+ saline group, AMPK-DN+ scopolamine group, and AMPK-WT+ scopolamine group. The AMPK-DN+ scopolamine group exhibited markedly diminished cholinergic activity that was characterized by reduced AChE-reactive neurons when compared with the AMPK-DN+ saline group, but the AMPK-WT+ scopolamine group was not influenced by scopolamine treatment.

As shown in Fig. 3B, the density of AChE-reactive neurons was lower in the AMPK-DN+ saline group than in the AMPK-DN+ saline group. The density of the AChE neurons in the CA1 area was 63.71±4.10 (99.95±6.45%) in the AMPK-DN+ saline group, 52.64±3.55 (82.64±5.57%) in the AMPK-DN+ scopolamine group, and 63.65±2.45 (99.89±3.85%) in the AMPK-WT+ scopolamine group [F(2, 115)=3.850, p<0.05]. Post hoc analysis revealed that the density of the AChE reactive neurons in the hippocampus of the AMPK-WT+ scopolamine group (p<0.05) showed higher expression than that of the AMPK-DN+ scopolamine group (in CA1). The density of the AChE neurons at CA3 of the hippocampus was lower in the AMPK-DN+ saline group than the AMPK-DN+ saline group (Fig. 3C). The density of AChE neurons in the CA3 area was 78.07±3.90 (99.91±5.01%) in the AMPK-DN+ saline group, 64.91±2.67 (83.11±3.42%) in the AMPK-DN+ scopolamine group, and 69.64±2.35 (89.06±3.01%) in the AMPK-WT+ scopolamine group [F(2, 121)=3.173, p<0.05]. Post hoc analysis revealed that the density of the AChE reactive neurons in the hippocampus of the AMPK-DN+ saline group (p<0.05) was greater than that of the AMPK-DN+ scopolamine group (in CA3). These results suggest that AMPK-WT may contribute to the amelioration of the decreased learning capacity through alleviation of the cholinergic neuronal damages in the hippocampal pathway.

**Measurement of the phosphorylation levels of AMPK in the hippocampus**

To determine if CA3 of the hippocampus was infected with Ad-AMPK-WT or Ad-AMPK-DN, expression of AMPKs in the adenoviral-infected brain region was confirmed by western blot analysis and AMPK activation was determined based on the phosphorylation levels of AMPK (p-AMPK) (Fig. 4). The results showed that the expression of the p-AMPK protein in the hippocampus of the AMPK-WT+ scopolamine group (p<0.05) showed higher expression than that of the AMPK-DN+ scopolamine group (in CA1). The adenoviral gene transfer of Ad-AMPK-WT resulted in elevation of the p-AMPK protein level, indicating an approximately 17-fold induction when compared with the normal group. However, adenoviral gene transfer of the Ad-AMPK-DN did not lead to a further increase in the p-AMPK protein level.

**AMPK protects against cytotoxic effects of glutamate**

To determine if adenoviral gene transfer of AMPK affects...
cell apoptosis, we examined the effect of AMPK on glutamate-induced cytotoxicity in neuronal cells. After culture for seven days in vitro, hippocampal neurons were infected with Ad-AMPK-WT or Ad-AMPK-DN, after which they were exposed to glutamate and glycine. After excitotoxicity was induced, the cells were further incubated with the neuronal culture medium at 37°C and then analyzed by western blot assays. Pro-apoptotic Bax and anti-apoptotic Bcl-2 are crucial in determining cell survival or death. As shown in Fig. 5, glutamate induced an increase in the expression of Bax, which was responsible for permeabilization of the mitochondrial membrane, leading to the release of cytochrome c from the mitochondria and initiation of the caspase activation pathway for apoptosis [29]. This activation of Bax was markedly reversed in cells infected with Ad-AMPK-WT. In addition, the expression of Bcl-2, which has anti-apoptotic and cell survival-promoting effects [30], was significantly upregulated in cells infected with Ad-AMPK-WT when compared to the control cells; however, there was no significant difference in the levels of Bcl-2 between glutamate-treated cells and Ad-AMPK-WT+glutamate treated cells (No significant change in the expression levels of Bcl-2 was observed). Hence, this anti-apoptotic effect of AMPK was identified based on a decreased Bax/Bcl-2 ratio.

Our data show that infection with Ad-AMPK-WT generates a survival signal after glutamate treatment of the cells, suggesting that AMPK plays a protective role in glutamate-induced cytotoxicity.

We also analyzed the protective effect of AMPK against apoptosis by using flow cytometry. Annexin V (Mr 36-kDa), a member of the annexin family of calcium-dependent phospholipid binding proteins, has a high affinity for phosphatidylserine (PS) containing phospholipid bilayers. Fluorescein conjugates of annexin V can be used to monitor changes in cell membrane phospholipid asymmetry, thereby providing a convenient tool for the detection of apoptotic cells. Therefore, we used FITC-conjugated annexin V to assess the effects of AMPK on the apoptosis of primary hippocampal neuron [31]. As shown in Fig. 6, Ad-AMPK-DN infected cells showed a distinct shift in annexin fluorescence intensity (AMPK-DN; M1 51.29%). Conversely, the shift in fluorescence intensity was reduced in Ad-AMPK-WT infected cells (AMPK-WT; M1 43.07%). These data indicate that apoptosis, as assessed by annexin V staining, was attenuated in the primary hippocampal neuron in response to AMPK expression.

Fig. 4. Phosphorylation of AMPK (p-AMPK) in CA3 of the hippocampus infected with Ad-AMPK-WT or Ad-AMPK-DN. Western blot analysis (A) of lysates obtained from normal hippocampus and those following Ad-AMPK-WT and -DN infection were performed using antibodies phosphorylated (P-AMPK) or total AMPK α (AMPK α). The intensities obtained from gel image of (A) were depicted as the ratio between total AMPK and P-AMPK (B).

Fig. 5. The effect of AMPK on glutamate-induced apoptosis of cells. Hippocampal neurons cultured in vitro for seven days were transfected with Ad-AMPK-WT and Ad-AMPK-DN in each group and then exposed to 100 μM glutamate with 10 μM of glycine in supplemented neuronal culture medium for 15 min at 37°C. Western blot assays were then conducted using anti-Bax and anti-Bcl-2. The experiment was repeated three times with similar results.

Fig. 6. The effect of AMPK on the apoptosis of primary cultured hippocampal neurons as determined by FITC-conjugated annexin V. Neonatal rat hippocampal neurons were cultured and infected with Ad-AMPK-WT or Ad-AMPK-DN, followed by exposure to glutamate and glycine. Annexin V positive cells were detected by flow cytometry (FACS Calibur, BD, San Diego, CA, USA) and analyzed using the CellQuest software.
DISCUSSION

The nervous system accounts for a high proportion of total body energy turnover, and neurons are particularly susceptible to energy deficits due to their inflexible metabolism and poor capacity to store nutrients [32]. Therefore, it is not surprising that adenosine monophosphate-activated protein kinase (AMPK), which is part of the signaling system that is important to the maintenance of energy balance at both the cellular and whole body levels, is highly expressed in the central nervous system [8,33]. AMPK is activated following ATP depletion, an increase in AMP levels, or a rise in the AMP-ATP ratio within a cell [8,10,33]. Once activated, AMPK increases cellular ATP supply by stimulating glycolysis. Conversely, it suppresses the key enzymes involved in ATP-consuming anabolic pathways to maintain ATP level homeostasis [2,3], through inhibition of the ATP gated Cl− channel [34] and phosphorylation of the GABAB receptor to induce increased GABA-dependent inhibition of presynaptic Ca2+/calmodulin-dependent protein kinase be-

ta-mediated activation of AMPK. AMPK activation, in turn, leads to an increase in brain-derived neurotrophic factor expression that likely occurs via the action of nuclear factor-kappaB [38]. In addition, AMPK activation decreased cytoplasmic HuR (a shuttling RNA-binding protein), which consequently decreased the binding of HuR to target transcripts and diminished the expression and half-lives of such HuR target mRNA [39,40]. Researchers have also found that sustained AMPK activation by either AMPK activator or active AMPK mutant induced apoptosis [41-43]. For example, the sustained activation of AMPK induced apoptosis in liver cells through activation of c-Jun N-terminal kinase [44]. Some studies have demonstrated that overactivation or sustained activation of AMPK was detrimental to neurons [10]. However, the wider role of AMPK in the nervous system is still not clear.

ACKNOWLEDGEMENTS

This work was supported by the Korea Science and Engineering Foundation (KOSEF) grant funded by the Korea government (MEST) (No. 2009-0063466) and a Post-Doctoral fellowship from Kyung Hee University in 2009 (KHU-20090505).

REFERENCES

1. Gomez-Pinilla F, Vaynman S, Ying Z. Brain-derived neurotrophic factor functions as a metabotrophin to mediate the effects of exercise on cognition. Eur J Neurosci. 2008;28:2278-2287.
2. Hardie DG. The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell? Annu Rev Biochem. 1998;67:821-855.
3. Hardie DG. Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology. 2003;144:5179-5183.
4. Hardie DG. The AMP-activated protein kinase pathway- new players upstream and downstream. J Cell Sci. 2004;117:5479-5487.
5. Woods A, Azzouz-Mamiche D, Foretz M, Stein SC, Lemarchand P, Ferré P, Foufelle F, Carling D. Characterization of the role of AMP-activated protein kinase in the regulation of glucose-activated gene expression using constitutively active and dominant negative forms of the kinase. Mol Cell Biol. 2000;20:6704-6711.
6. Johnson LN, Noble ME, Owen DJ. Active and inactive protein kinases: structural basis for regulation. Cell. 1996;85:149-158.
17. Lee B, Lee I, Shim I, Lee H, Hahm D.H. McGee SL, Hargreaves M.
Schubert D, Piasecki D. Ray CA, Blin J, Chase TN, Piercey MF. Fan Y, Hu J, Li J, Yang Z, Xin X, Wang J, Ding J, Geng M.
Klinkenberg I, Blokland A. Albright TD, Jessell TM, Kandel ER, Posner MI. Föller M, Sopjani M, Koka S, Gu S, Mahmud H, Wang K, Zhao Y, Shen J, Su H, Li B, Xing D, Du L. Lee S, Kim Y, Li E, Park S.
Leon R, Wu H, Jin Y, Wei J, Buddahal C, Prentice H, Wu JY. Stein SC, Woods A, Jones NA, Davison MD, Carling D. Cmuc C, Monnig J, Kemp BE, Mattson MP. McGee SL, Hargreaves M.
Cuddefull AE, Pearson T, Currie AJ, Dale N, Hawley SA, Sheehan M, Hirst W, Michel AD, Randall A, Artcliffe DG, Frenguelli BG. McGee SL, Hargreaves M. McGee SL, Hargreaves M. McGee SL, Hargreaves M.
Gadalla AE, Pearson T, Currie AJ, Dale N, Hawley SA, Zhao Y, Shen J, Su H, Li B, Xing D, Du L.
Gadalla AE, Pearson T, Currie AJ, Dale N, Hawley SA, Sheehan M, Hirst W, Michel AD, Randall A, Artcliffe DG, Frenguelli BG. McGee SL, Hargreaves M. McGee SL, Hargreaves M. McGee SL, Hargreaves M. McGee SL, Hargreaves M.
Gadalla AE, Pearson T, Currie AJ, Dale N, Hawley SA, Sheehan M, Hirst W, Michel AD, Randall A, Artcliffe DG, Frenguelli BG. McGee SL, Hargreaves M. McGee SL, Hargreaves M. McGee SL, Hargreaves M. McGee SL, Hargreaves M. McGee SL, Hargreaves M.
Gadalla AE, Pearson T, Currie AJ, Dale N, Hawley SA, Sheehan M, Hirst W, Michel AD, Randall A, Artcliffe DG, Frenguelli BG. McGee SL, Hargreaves M. McGee SL, Hargreaves M. McGee SL, Hargreaves M. McGee SL, Hargreaves M. McGee SL, Hargreaves M. McGree BL, Beattie BG, Means AR.
18. Klinkenberg I, Blokland A. Albright TD, Jessell TM, Kandel ER, Posner MI. Föller M, Sopjani M, Koka S, Gu S, Mahmud H, Wang K, Zhao Y, Shen J, Su H, Li B, Xing D, Du L. Lee S, Kim Y, Li E, Park S.
Leon R, Wu H, Jin Y, Wei J, Buddahal C, Prentice H, Wu JY. Stein SC, Woods A, Jones NA, Davison MD, Carling D. Cmuc C, Monnig J, Kemp BE, Mattson MP. McGee SL, Hargreaves M.
Cuddefull AE, Pearson T, Currie AJ, Dale N, Hawley SA, Sheehan M, Hirst W, Michel AD, Randall A, Artcliffe DG, Frenguelli BG. McGee SL, Hargreaves M. McGee SL, Hargreaves M. McGee SL, Hargreaves M. McGee SL, Hargreaves M. McGee SL, Hargreaves M. McGee SL, Hargreaves M. McGree BL, Beattie BG, Means AR.
19. Klinkenberg I, Blokland A. Albright TD, Jessell TM, Kandel ER, Posner MI. Föller M, Sopjani M, Koka S, Gu S, Mahmud H, Wang K, Zhao Y, Shen J, Su H, Li B, Xing D, Du L. Lee S, Kim Y, Li E, Park S.
Leon R, Wu H, Jin Y, Wei J, Buddahal C, Prentice H, Wu JY. Stein SC, Woods A, Jones NA, Davison MD, Carling D. Cmuc C, Monnig J, Kemp BE, Mattson MP. McGee SL, Hargreaves M.
Cuddefull AE, Pearson T, Currie AJ, Dale N, Hawley SA, Sheehan M, Hirst W, Michel AD, Randall A, Artcliffe DG, Frenguelli BG. McGee SL, Hargreaves M. McGee SL, Hargreaves M. McGee SL, Hargreaves M. McGee SL, Hargreaves M. McGee SL, Hargreaves M. McGee SL, Hargreaves M. McGree BL, Beattie BG, Means AR.
19. Klinkenberg I, Blokland A. Albright TD, Jessell TM, Kandel ER, Posner MI. Föller M, Sopjani M, Koka S, Gu S, Mahmud H, Wang K, Zhao Y, Shen J, Su H, Li B, Xing D, Du L. Lee S, Kim Y, Li E, Park S.
Leon R, Wu H, Jin Y, Wei J, Buddahal C, Prentice H, Wu JY. Stein SC, Woods A, Jones NA, Davison MD, Carling D. Cmuc C, Monnig J, Kemp BE, Mattson MP. McGee SL, Hargreaves M.
Cuddefull AE, Pearson T, Currie AJ, Dale N, Hawley SA, Sheehan M, Hirst W, Michel AD, Randall A, Artcliffe DG, Frenguelli BG. McGee SL, Hargreaves M. McGee SL, Hargreaves M. McGee SL, Hargreaves M. McGee SL, Hargreaves M. McGee SL, Hargreaves M. McGee SL, Hargreaves M. McGree BL, Beattie BG, Means AR.
19. Klinkenberg I, Blokland A. Albright TD, Jessell TM, Kandel ER, Posner MI. Föller M, Sopjani M, Koka S, Gu S, Mahmud H, Wang K, Zhao Y, Shen J, Su H, Li B, Xing D, Du L. Lee S, Kim Y, Li E, Park S.
Leon R, Wu H, Jin Y, Wei J, Buddahal C, Prentice H, Wu JY. Stein SC, Woods A, Jones NA, Davison MD, Carling D. Cmuc C, Monnig J, Kemp BE, Mattson MP. McGee SL, Hargreaves M.
Cuddefull AE, Pearson T, Currie AJ, Dale N, Hawley SA, Sheehan M, Hirst W, Michel AD, Randall A, Artcliffe DG, Frenguelli BG. McGee SL, Hargreaves M. McGee SL, Hargreaves M. McGee SL, Hargreaves M. McGee SL, Hargreaves M. McGee SL, Hargreaves M. McGee SL, Hargreaves M. McGree BL, Beattie BG, Means AR.